RGEN: Repligen Corporation Stock

by  •  • Comments Off on RGEN: Repligen Corporation Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 7,144.34
Enterprise Value ($M) 6,912.55
Book Value ($M) 2,016.69
Book Value / Share 35.92
Price / Book 3.54
NCAV ($M) 209.09
NCAV / Share 3.72
Price / NCAV 34.17

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.01

Liquidity (mrq)
Quick Ratio 7.28
Current Ratio 8.41

Balance Sheet (mrq) ($M)
Current Assets 1,066.04
Assets 2,829.67
Liabilities 856.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 634.44
Operating Income 44.96
Net Income -25.51
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 175.39
Cash from Investing -86.38
Cash from Financing -82.90

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Price T Rowe Associates Inc /md/ 12.70 11.64
02-13 13G/A Eddleman Roy T 4.84 0.00
11-12 13G/A BlackRock, Inc. 12.70 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-01 95,693 620,657 15.42
2025-03-31 155,533 980,566 15.86
2025-03-28 117,697 782,662 15.04
2025-03-27 40,997 254,680 16.10

(click for more detail)

Similar Companies
RDUS – Radius Recycling, Inc. REGN – Regeneron Pharmaceuticals, Inc.
REPL – Replimune Group, Inc. RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io